| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 interim results example | gotistobart (BNT316/ONC-392) metastatic squamous non-small cell lung cancer (NSCLC) progressed after platinum-based chemotherapy and PD-(L)1 therapy | Phase 3 | — | Biologics | Oncology | ||
Phase 3 interim results example | gotistobart (BNT316/ONC-392) metastatic squamous non-small cell lung cancer (NSCLC) progressed after platinum-based chemotherapy and PD-(L)1 therapy | Phase 3 | — | Biologics | Oncology | ||
Phase 3 interim results example | gotistobart (BNT316/ONC-392) metastatic squamous non-small cell lung cancer (NSCLC) progressed after platinum-based chemotherapy and PD-(L)1 therapy | Phase 3 | — | Biologics | Oncology |
Recent Updates
Recently added Catalysts
BioNTech SE$93.32
+0.27 (+0.29%)
A 80Pipeline Score Fair Value Biotech · Commercial
Market Cap
23.30 B
EPS
-5.87
P/E Ratio
-
Value Trade
58.32 M
2.04 %
Week
-18.02 %
1 Month
-15.61 %
3 Month
-5.52 %
6 Month
-53.35 %
5 Year
458.42 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
346.97 K
52 Week Range
79.52 - 124
% held by Insiders
0.37 %
% held by Institutions
19.66 %
Enterprise Value
6.79 B
Total Shares
252.88 M
Short %
1.09 %
Float Shares
251.94 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioNTech SE
658Total events
3Upcoming
259Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 3
Event history 655
Jun 1, 2026
◆Poster Presentationtrastuzumab pamirtecanPresentation
Phase 3 trial of trastuzumab pamirtecan (HER2 ADC) vs chemo in HER2-expressing recurrent EC
recurrent endometrial cancersource ↗
May 31, 2026
◆Poster PresentationPumitamigPresentation
Phase 2/3 trial of pumitamig + chemotherapy vs bevacizumab + chemotherapy in 1L CRC
Colorectal cancersource ↗
May 31, 2026
◆Poster PresentationBNT324/DB-1311Presentation
Phase 3 trial of BNT324/DB-1311 (B7H3 ADC) vs docetaxel in taxane-naïve mCRPC
Metastatic castration-resistant prostate cancersource ↗
May 30, 2026
◆Oral PresentationPumitamigPresentation
Phase 2 data from ROSETTA Lung-02 for pumitamig + chemo in 1L NSCLC
first-line non-small cell lung cancersource ↗
May 30, 2026
●Enrollment UpdatePumitamigTrial
Phase 3 part of ROSETTA Lung-02 currently recruiting
non-small cell lung cancersource ↗
May 30, 2026
●Trial InitiationPumitamigTrial
ROSETTA Lung-201 Phase 3 trial currently enrolling
non-small cell lung cancersource ↗
May 30, 2026
◆Oral PresentationGotistobartPresentation
Overall survival for patients with pre-treated PROC receiving gotistobart + pembrolizumab
Platinum-resistant ovarian cancersource ↗
May 30, 2026
◆Poster PresentationBNT326/YL202Presentation
Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig
advanced solid tumorssource ↗
May 29, 2026
◆Topline ReadoutPumitamigClinical Data
Phase 2 data expected at ASCO 2026
first-line non-small cell lung cancersource ↗
May 15, 2026
●Quarterly UpdateCorporate
Annual General Meeting 2026 held; shareholders approved all agenda items including board expansion
May 7, 2026
Drug Pipeline Intelligence
A80
Pipeline Score $47.6B
Pipeline ValueFair Value
Valuation Signal57
Drugs Scored2.0x
rNPV / MCap Top 97%
Mid Cap (rank 28 of 905)
Percentile RankBioNTech SE earns an A-grade pipeline score (80/100), with $56.4B risk-adjusted pipeline value, led by BNT162b2 in SARS-CoV-2 Infection (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BNT162b2 Monoclonal antibody | COVID-19 | Phase 3 | NCT07222384 | 65% | $9.0B | ACTIVE NOT_RECRUITING | 6,357 | SLOW | D (34) | Jul 31, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
gotistobart | squamous non-small cell lung cancer | Phase 3 | 2025-12-08 | |||
gotistobart | squamous non-small cell lung cancer | Phase 3 | 2025-12-08 | |||
gotistobart | squamous non-small cell lung cancer | Phase 3 | 2025-12-08 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BNTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BNTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BNTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BNTXGlobal Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
BioNTech and Bristol Myers Squibb announced promising interim Phase 2 data from the ROSETTA Lung-02 trial, showing high response rates for the bispecific immunomodulator pumitamig in patients with advanced non-small cell lung cancer. The trial demonstrated significant anti-tumor activity across different PD-L1 expression levels, with manageable safety profiles. The companies are advancing further studies to evaluate pumitamig's efficacy.
Read more →BNTXBioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
BioNTech will present new clinical data from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting. Key highlights include promising results for pumitamig in non-small cell lung cancer and gotistobart in platinum-resistant ovarian cancer. The company is advancing over 25 Phase 2 and Phase 3 trials, focusing on innovative treatment combinations.
Read more →BNTXBioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung
BioNTech presented promising data at the ASCO Annual Meeting 2026 regarding its late-stage clinical development programs. Key highlights include encouraging results for Pumitamig in non-small cell lung cancer and Gotistobart in platinum-resistant ovarian cancer. The company continues to advance its oncology pipeline with over 25 clinical studies, including innovative combination therapies.
Read more →BNTXAktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu
BioNTech SE held its annual general meeting where shareholders approved all agenda items, including the expansion of the supervisory board. The company is intensifying its focus on oncology, adding two new board members with significant experience in clinical development and oncology. This strategic move aims to bolster BioNTech's capabilities in addressing cancer treatments.
Read more →BNTXBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
BioNTech SE held its Annual General Meeting where shareholders approved all agenda items, including the expansion of the Supervisory Board. New members with expertise in oncology and clinical development were elected. The company aims to enhance its late-stage oncology pipeline while continuing early research efforts.
Read more →BNTXBioNTech Announces New ADS Repurchase Program
BioNTech has announced a new share repurchase program allowing for the repurchase of up to $1 billion in American Depositary Shares until May 6, 2027. This initiative is part of the company's strategy to enhance capital efficiency and support long-term growth. The program will be funded using existing cash resources and is designed to operate within regulatory safe harbors.
Read more →BNTXUNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Interim Condensed Consolidated Statements of Profit or Loss 1 Interim Condensed Consolidated Statements of Comprehensive Income 2 Interim Condensed Consolidat
BioNTech SE has released its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026. The company reported a net loss of €531.9 million, a decline from €415.8 million in the same period last year. Revenues also fell significantly, amounting to €118.1 million compared to €182.8 million in the prior year. Additionally, total assets decreased from €21,988.6 million to €21,074.1 million over the same time frame.
Read more →BNTXBioNTech Announces First Quarter 2026 Financial Results and Corporate Update
BioNTech reported its first quarter 2026 financial results, highlighting a net loss of €531.9 million and revenues of €118.1 million, down from €182.8 million the previous year. The company initiated five pivotal trials for its oncology drug pumitamig and reaffirmed its financial guidance for the year. BioNTech also plans a share repurchase program of up to $1 billion to enhance capital efficiency.
Read more →BNTXBioNTech veröffentlicht am 5. Mai 2026 Ergebnisse für das erste Quartal 2026 und informiert über operativen Fortschritt
BioNTech SE will release its Q1 2026 financial results on May 5, 2026. The company will also hold a conference call and webcast for investors and the public to discuss the results and provide an operational update. The event highlights BioNTech's commitment to transparency and engagement with stakeholders.
Read more →BNTXBioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
BioNTech SE will report its financial results for the first quarter of 2026 on May 5, 2026. A conference call and webcast will follow at 8:00 a.m. ET to discuss these results and provide a corporate update. Investors and the public can access the call via registration, with a replay available afterward.
Read more →BNTXBioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
BioNTech announced positive results from a Phase 2 trial of trastuzumab pamirtecan for HER2-expressing endometrial cancer. The treatment showed a confirmed objective response rate of 49.3% among patients previously treated with checkpoint inhibitors. Safety data indicated a manageable profile, with common adverse events including low-grade nausea and anemia. The findings will be presented at the SGO Annual Meeting.
Read more →BNTXBioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
BioNTech presented significant data on its late-stage lung cancer portfolio at the ELCC 2026, highlighting the potential of its candidates pumitamig and gotistobart. The results from multiple clinical trials indicate promising efficacy and safety profiles, particularly in treating advanced lung cancer. The company aims to provide transformative treatment options across all stages of the disease.
Read more →BNTXBioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs
BioNTech showcased advancements in its late-stage lung cancer programs at the ELCC 2026. The data updates highlighted the potential of its differentiated portfolio, including promising results for Pumitamig and Gotistobart. These candidates aim to provide innovative treatment options for various lung cancer stages, addressing significant unmet medical needs.
Read more →BNTXThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioN
BioNTech recently presented its 2025 financial results and corporate update, highlighting a robust financial standing with $17.2 billion in cash. The company is continuing its leadership in the COVID-19 vaccine market while advancing its oncology programs. In addition, BioNTech is in the process of transitioning management responsibilities and exploring the contribution of certain assets to an independent company. However, the presentation outlines various risks associated with leadership transitions, clinical trial uncertainties, and competitive pressures.
Read more →BNTXBioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
BioNTech SE is currently under investigation by Johnson Fistel, PLLP regarding potential investor claims following financial disclosures that revealed a significant net loss of approximately €305 million for Q4 2025. The company also reported a decline in demand for its COVID-19 vaccines, contributing to reduced revenue. Additionally, BioNTech's founders have announced their intention to leave the company by the end of 2026 to pursue a new venture. The investigation aims to determine whether BioNTech complied with federal securities laws amid these challenging circumstances.
Read more →BNTXBioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
Read more →BNTXBioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
Read more →BNTXBioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt
BioNTech SE will announce its fourth quarter and fiscal year 2025 results on March 10, 2026. The company will also host a conference call and webcast for investors and analysts to discuss the financial outcomes and provide a corporate update. This event highlights BioNTech's ongoing commitment to transparency and investor engagement.
Read more →BNTXBioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
BioNTech SE will announce its fourth quarter and full year 2025 financial results on March 10, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss these results and provide a corporate update. Investors and the public can access the call and related materials through the company's website.
Read more →BNTXBioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
BioNTech SE has appointed Kylie Jimenez as Chief People Officer, effective March 1, 2026. This strategic move aims to enhance the company's workforce capabilities as it transitions into a multi-product oncology firm by 2030. Jimenez, with over two decades of HR experience, will lead initiatives to attract and retain talent while fostering an inclusive culture.
Read more →BNTXBioNTech ernennt Kylie Jimenez zur neuen Personalvorständin
BioNTech has appointed Kylie Jimenez as Chief People Officer effective March 1, 2026. This strategic move aims to enhance the company's workforce in line with its goal of becoming an oncology leader by 2030. Jimenez, with extensive international HR experience, will lead talent acquisition and foster an inclusive culture.
Read more →BNTXThis Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not
BioNTech presented a slide presentation at the 44th J.P. Morgan Healthcare Conference outlining its forward-looking statements and anticipated developments for its COVID-19 vaccine and other investigational medicines. The presentation highlighted BioNTech's strong performance with over 5 billion vaccine doses distributed and more than 25 ongoing clinical trials. Additionally, the strategic focus on oncology and AI-driven innovations was emphasized as critical components in advancing their research endeavors.
Read more →BNTXBioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Read more →BNTXConvenience Translation. The German version is authoritative ARTICLES OF ASSOCIATION OF BIONTECH SE I. General Provisions 1 Company Name, Registered Office and Financial Year (1) The name of the Company is "BioNTech SE".
The article presents a convenience translation of the Articles of Association for BioNTech SE. It outlines the company's governance related to share issuance, including subscription rights for shareholders and conditions under which these rights may be excluded. Additionally, it touches on the mechanism for amending the Articles of Association by the Supervisory Board and specifies judicial jurisdiction concerning capital market laws in the United States.
Read more →BNTXBioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field BioNTech has completed its exchange offer to acquire CureVac Acquisition complements Bi
BioNTech SE has finalized its acquisition of CureVac N.V., officially closing the exchange offer for all outstanding shares. With approximately 86.75% of CureVac's shares validly tendered, BioNTech aims to enhance its mRNA design and manufacturing capabilities. The acquisition supports BioNTech's oncology strategy, particularly in developing mRNA-based therapies. Following the acquisition, members from BioNTech will now lead the CureVac Management Board, ensuring continuity in operations.
Read more →BNTXBioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Read more →BNTXBioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
BioNTech and OncoC4 reported promising results from the Phase 3 trial of gotistobart for squamous non-small cell lung cancer (sqNSCLC). The treatment demonstrated a significant overall survival benefit compared to standard chemotherapy, with a 63.1% survival rate at 12 months. The safety profile was manageable, and further investigation is ongoing in a pivotal trial stage.
Read more →BNTXBioNTech Achieves Minimum Condition in CureVac Exchange Offer The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstand
BioNTech SE has announced the successful completion of the minimum condition for its exchange offer of CureVac N.V. shares, with 81.74% of CureVac's issued shares tendered. Following this, all closing conditions related to the post-offer reorganization have been fulfilled. BioNTech will now proceed to deliver its American Depositary Shares to those who participated in the exchange. Additionally, a subsequent offering period has been initiated for CureVac shareholders who have yet to tender their shares.
Read more →BNTXBioNTech informiert über Fortschritte im Rahmen des Umtauschangebots für CureVac-Aktien und weist auf Ablauf des Angebots am 3. Dezember 2025 um 15 Uhr MEZ hin
BioNTech announced that its exchange offer for CureVac shares received overwhelming approval from CureVac shareholders, with over 99.16% voting in favor. The exchange offer is set to close on December 3, 2025, and shareholders are advised to submit their shares by December 2, 2025, to ensure timely processing. The exchange ratio is established at 0.05363 BioNTech ADS per CureVac share, based on recent trading data.
Read more →BNTXBioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
BioNTech SE has announced the approval of its exchange offer for CureVac N.V. shares, with over 99.16% of CureVac shareholders voting in favor. The offer is set to expire on December 3, 2025, and shareholders must tender their shares by December 2, 2025. The exchange ratio is established at 0.05363 BioNTech ADS per CureVac share, based on recent trading prices.
Read more →BNTXIntroductory Remarks Douglas Maffei, PhD, Vice President, Strategy and Investor Relations 1 3 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the m
The presentation by BioNTech's Vice President of Strategy and Investor Relations, Douglas Maffei, reflects on forward-looking statements related to the company's expected performance, particularly concerning its COVID-19 vaccine, COMIRNATY. It addresses anticipated changes in vaccine demand and ongoing clinical and preclinical R&D programs. Additionally, the presentation highlights risks associated with regulatory approvals, trial timelines, and market competition. BioNTech also discusses its collaborations, including a partnership with BMS and plans for the acquisition of CureVac.
Read more →BNTXBioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung
BioNTech SE reported its Q3 2025 results, highlighting significant revenue growth driven by collaborations, particularly with Bristol Myers Squibb. The company is advancing its oncology strategy and has increased its revenue forecast for the year. However, it also reported a net loss for the quarter, influenced by reduced sales of COVID-19 vaccines.
Read more →BNTXBioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
BioNTech SE reported its Q3 2025 financial results, highlighting significant advancements in its oncology programs and a revenue increase driven by collaborations. The company has raised its full-year revenue guidance to €2.6-2.8 billion, despite facing a net loss in the quarter. Ongoing partnerships, particularly with Bristol Myers Squibb, are expected to enhance their therapeutic offerings.
Read more →BNTXBioNTech veranstaltet am 11. November 2025 „Innovation Series Day“ zu Forschung & Entwicklung
BioNTech SE is set to hold its 'Innovation Series Day' on November 11, 2025, in New York City. The event will feature updates on the company's strategy and pipeline developments, aimed at investors, analysts, and the public. The presentation will be available online for a year after the event.
Read more →BNTXBioNTech to Host Innovation Series R&D Day on November 11, 2025
BioNTech SE will host its Innovation Series R&D Day on November 11, 2025, in New York City. The event aims to provide insights into the company's strategy and clinical advancements. Investors and the public can join online, with a replay available afterward. BioNTech continues to innovate in immunotherapy and mRNA vaccine development.
Read more →BNTXBioNTech veröffentlicht am 3. November 2025 Ergebnisse für das dritte Quartal 2025 und informiert über operativen Fortschritt
BioNTech SE is set to release its Q3 2025 results on November 3, 2025. The company will host a conference call and webcast for investors and analysts to discuss the financial outcomes and operational updates. BioNTech continues to develop a diverse range of therapies, including mRNA cancer immunotherapies.
Read more →BNTXBioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Read more →BNTXBioNTech beginnt öffentliches Umtauschangebot für alle ausstehenden Aktien von CureVac N.V.
BioNTech has initiated a public exchange offer for all outstanding shares of CureVac, following a previously announced purchase agreement. This merger aims to strengthen BioNTech's capabilities in mRNA research and development, particularly in cancer immunotherapy. The exchange offer values CureVac at approximately $1.25 billion and is set to close on December 3, 2025, pending certain conditions.
Read more →BNTXBioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
BioNTech has initiated a public exchange offer for all outstanding shares of CureVac, aiming to merge their mRNA technologies to enhance cancer immunotherapy development. The acquisition, valued at approximately $1.25 billion, is part of BioNTech's oncology strategy and is expected to create long-term shareholder value. The Offer is contingent on regulatory approvals and shareholder participation.
Read more →BNTXThis slide presentation includes forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, for
BioNTech SE presents its forward-looking statements during its AI Day 2025, emphasizing advancements in AI integration within their oncology programs. The company aims to leverage disruptive technology to create innovative treatments, enhancing their immunotherapeutic capabilities. BioNTech showcases its global reach with various AI centers and outlines its strategy for addressing high unmet medical needs in cancer treatment. The presentation indicates commitment to collaboration, notably with InstaDeep, to propel AI developments.
Read more →BNTXBioNTech veranstaltet am 1. Oktober 2025 zweiten „AI Day“ als eine Ausgabe der „Innovation Series“
BioNTech SE is set to host its second AI Day on October 1, 2025, in London, in collaboration with its AI subsidiary, InstaDeep Ltd. The event will provide insights into BioNTech's AI strategy and its applications in their pipeline. It will be live-streamed and recorded for future access on their website.
Read more →BNTXBioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
BioNTech SE will host its second AI Day on October 1, 2025, in London, focusing on its AI strategy and applications in its pipeline. The event aims to provide insights into how AI is integrated into BioNTech's operations. A live webcast will be available, along with access to event materials post-event.
Read more →BNTXFirst Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327 BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouragin
BioNTech and Bristol Myers Squibb unveiled encouraging interim Phase 2 data for their bispecific antibody pumitamig (BNT327 BMS986545) in extensive-stage small cell lung cancer (ES-SCLC). The data revealed a 76.3% confirmed objective response rate and a 100% disease control rate, with manageable safety signals. The positive trends in progression-free survival and treatment response suggest pumitamig could potentially establish a new standard of care for patients with this aggressive cancer type. A pivotal Phase 3 trial is currently ongoing to further evaluate its efficacy.
Read more →BNTXCertain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. EXECUTION VERSION AMENDE
The article discusses a significant amendment and restatement of a global co-development and co-commercialization agreement involving Bristol-Myers Squibb and BioNTech. The document outlines various articles related to definitions, development plans, commercialization strategies, and financial provisions among other key elements. It emphasizes strategic collaboration, regulatory matters, and the governance structure to enhance efficacy in their partnership. Many sections cover critical operational aspects such as intellectual property and manufacturing obligations, solidifying the framework for their collaboration.
Read more →BNTXPfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Read more →BNTXBioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
Read more →BNTXBioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
Read more →BNTXBioNTech Announces Ryan Richardson to Step Down from the Management Board
BioNTech Announces Ryan Richardson to Step Down from the Management Board
Read more →BNTXExecution Version PURCHASE AGREEMENT dated as of
BioNTech SE has entered into a Purchase Agreement to acquire CureVac N.V. The agreement outlines the terms and conditions of an exchange offer for CureVac's shares, with support from both companies' management and supervisory boards. The deal aims to bolster BioNTech's position in the biopharmaceutical market, with both parties expressing confidence in the strategic benefits of the acquisition.
Read more →BNTXBioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidate
BioNTech SE has initiated a public exchange offer to acquire CureVac N.V. in an all-stock transaction valued at approximately $1.25 billion. This acquisition aims to strengthen BioNTech's capabilities in mRNA-based cancer immunotherapy and enhance its ongoing oncology strategy. By bringing together their complementary technologies and research efforts, both companies aspire to establish new standards of care for various cancer types. The transaction, which has received unanimous approval from both companies' boards, is expected to close in 2025 pending regulatory approvals and minimum shareholder acceptance.
Read more →BNTXBioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
Read more →BNTXBioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
Read more →BNTXBioNTech Announces First Quarter 2025 Financ ial Results and Corporate Update Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs next-generation immunomodulator BNT327, a bi
BioNTech reported its financial results for the first quarter of 2025, highlighting a focus on its oncology pipeline and new immunomodulator BNT327. The company presented clinical updates indicating progress with its cancer treatment strategies, while maintaining a robust cash position of 15.9 billion. Although revenue slightly declined and net losses increased, BioNTech confirmed its financial guidance for the year, emphasizing continued investment in research and development. The outlook remains positive amid the challenges facing the company, including legal disputes and the evolving market for COVID-19 vaccines.
Read more →BNTXBioNTech Announces Appointment of Ram n Zapata to Management Board as Chief Financial Officer Mainz, Germany
BioNTech SE has appointed Ram n Zapata-Gomez as the new Chief Financial Officer effective July 1, 2025. He succeeds Jens Holstein who will retire after his term. Zapata brings extensive financial expertise from his role at Novartis AG and is expected to play a crucial role in aligning BioNTech's financial direction with its strategy as a multi-product oncology company. His focus will be on optimizing financial performance in key markets as the company prepares to launch its oncology products.
Read more →BNTXBioNTech Announces First Quarter 2025 Financial Results and Corporate Update
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
Read more →BNTXBioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
Read more →BNTXBioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
Read more →BNTXEnglish Convenience Translation - the German language version is decisive BioNTech SE Mainz WKN A0V9BC ISIN DE000A0V9BC4 WKN A2PSR2 ISIN US09075V1026 Invitation to the Annual General Meeting 2025 Unique identifier of the
BioNTech SE has invited shareholders to its Annual General Meeting scheduled for May 16, 2025. The meeting will be conducted virtually, and shareholders can participate electronically. The agenda includes the presentation of financial statements for 2024, resolutions regarding profit appropriation, and the approval of actions taken by management and supervisory boards. Shareholders will also vote on the appointment of auditors for the upcoming financial year.
Read more →BNTXBioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Read more →BNTXBioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
Read more →BNTXBioNTech Completes Acquisition of Biotheus
BioNTech Completes Acquisition of Biotheus
Read more →BNTXBioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Read more →BNTXBioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech to Acquire Biotheus to Boost Oncology Strategy
Read more →BNTXBioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
Read more →BNTXBioNTech to Host Innovation Series R&D Day on November 14, 2024
BioNTech to Host Innovation Series R&D Day on November 14, 2024
Read more →BNTXBioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
Read more →BNTXBioNTech Highlights AI Capabilities and R D Use Cases at Inaugural AI Day Provides updates on BioNTech's strategy to scale and deploy AI-capabilities across the immunotherapy pipeline Highlights InstaDeep's new near exas
BioNTech highlights its AI capabilities and research applications during the inaugural AI Day. The company outlines its strategy to integrate advanced AI technologies across its immunotherapy pipeline, including the unveiling of a new near exascale supercomputer, Kyber, and novel AI models for protein generation. BioNTech, in collaboration with its AI subsidiary InstaDeep, aims to enhance personalized vaccines and targeted therapies. The updates focus on the synergy between biotechnology and AI, and the event showcases BioNTech's efforts in scaling its AI capabilities.
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Read more →BNTXBioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
Read more →BNTXBioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
Read more →BNTXPfizer and BioNTech Receive U.S. FDA Approval Authorization for Omicron KP.2-adapted COVID-19 Vaccine The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended
Pfizer and BioNTech have received FDA approval for their Omicron KP.2-adapted COVID-19 vaccine, recommended for individuals aged 6 months and older. This new vaccine is tailored to the KP.2 strain of the Omicron JN.1 lineage and aims to improve immunity against currently circulating variants. The decision to adapt the vaccine comes as cases of COVID-19 rise again, and shipping will begin immediately to ensure availability. The approval is backed by evidence supporting the vaccine's safety and efficacy.
Read more →BNTXPfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age In a Phase 3 trial, Pfizer and BioNTech's combination vaccine candidate agains
Pfizer and BioNTech provided an update regarding their Phase 3 trial of a combination mRNA vaccine for influenza and COVID-19. While the candidate met one of its primary immunogenicity objectives, it failed to achieve non-inferiority for the influenza B strain. The companies noted encouraging results for influenza A and are assessing next steps. Additionally, a separate Phase 2 trial for a second-generation trivalent influenza vaccine showed promising data.
Read more →BNTXBioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
Read more →BNTXThis Slide Presentation Includes Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but n
BioNTech reported its financial results for Q2 2024, highlighting significant achievements such as partnerships and positive clinical trial outcomes. The company has initiated a global rollout of variant-adapted COVID-19 vaccines. However, it acknowledged uncertainties related to COVID-19 vaccine demand and the challenges posed by emerging variants. The report includes forward-looking statements about the anticipated future of its products and ongoing research programs.
Read more →BNTXBioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
Read more →BNTXBioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for
Pfizer and BioNTech have received a positive opinion from the CHMP for their Omicron JN.1-adapted COVID-19 vaccine, which is recommended for individuals aged 6 months and older. This recommendation is based on data indicating that the vaccine produces a stronger immune response against JN.1 sublineages compared to previous vaccines. The European Commission will soon review this recommendation for final approval, with doses ready to ship immediately upon authorization, highlighting preparedness for the upcoming vaccination season.
Read more →BNTXBioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324 DB-1311 in Prostate Cancer Designation is based on pre-clinical data and data from an ongoing Phase 1 2 trial for BN
BioNTech and DualityBio have received FDA Fast Track designation for their antibody-drug conjugate BNT324 DB-1311, aimed at the treatment of advanced metastatic castration-resistant prostate cancer. This designation allows for expedited development and regulatory review based on preliminary positive clinical data showing antitumor activity. The ongoing Phase 1/2 trial has highlighted a manageable safety profile for BNT324 DB-1311. Additionally, this marks the third candidate from their collaboration to gain Fast Track status, reinforcing the potential of their ADC technology in addressing serious medical needs.
Read more →BNTXInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Read more →BNTXBioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem BioNTech and CEPI aim to enhance local R D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in
BioNTech and CEPI have expanded their partnership to enhance mRNA vaccine manufacturing capabilities in Kigali, Rwanda, with a funding commitment of up to $145 million. This initiative aims to create a sustainable vaccine ecosystem in Africa, focusing on equitable access and local manufacturing. The partnership will prioritize affordable vaccine production for low- and middle-income countries, particularly in response to future epidemic threats. Both organizations emphasize the importance of this effort in addressing historical vaccine inequities in Africa.
Read more →BNTXBioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
Read more →BNTXBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
BioNTech SE held its Annual General Meeting on May 17, 2024, where shareholders approved all proposed agenda items by a significant majority. The company highlighted its success in the COVID-19 vaccine market and reported advancements in its oncology pipeline, expressing optimism about its future product launches. The leadership emphasized BioNTech's robust financial position and readiness to transition into a multi-product company, primarily focusing on oncology treatments. Voting results and presentations from the AGM are available on the company's website.
Read more →BNTXBioNTech Announces First Quarter 2024 Financial Results and Corporate Update
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
Read more →BNTXUnaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 1 Interim Condensed Consolidated Statements of Comprehensive Income 2 Interim Condensed Consolidat
BioNTech SE reported significant financial losses in their quarterly results for Q1 2024. Revenues sharply declined to 187.6 million euros compared to 1,277.0 million euros in the same quarter of the previous year. The company posted an operating loss of 507.2 million euros, down from a profit of 654.4 million euros a year ago. Additionally, they experienced a net loss of 315.1 million euros, rising concerns over their financial health during this period.
Read more →BNTXBioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
Read more →BNTXDocument BioNTech SE Mainz WKN A0V9BC ISIN DE000A0V9BC4 WKN A2PSR2 ISIN US09075V1026 Invitation to the Annual General Meeting 2024 Unique identifier of the event 2008339965e7ee11b53000505696f23c Ladies and Gentlemen, We
BioNTech SE has invited its shareholders to participate in the Annual General Meeting scheduled for May 17, 2024. The meeting will take place virtually, allowing electronic participation for registered shareholders and their proxies. Shareholders can expect discussions on the financial results of 2023, including a proposed profit carry-forward. Additionally, the company will present a new Compensation System aimed at increasing the share of long-term variable compensation for executive members.
Read more →BNTXThree-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer Three-year follow-
BioNTech reported positive three-year follow-up data from a Phase 1 trial of its individualized mRNA cancer vaccine candidate, autogene cevumeran, in patients with resected pancreatic ductal adenocarcinoma (PDAC). The vaccine exhibited persistent T cell responses and delayed tumor recurrence in about half of the patients studied. A randomized Phase 2 clinical trial is currently underway to further evaluate the efficacy of this treatment against PDAC, reflecting a growing commitment to personalized cancer therapies. These findings were highlighted at the American Association for Cancer Research Annual Meeting 2024.
Read more →BNTXBioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Read more →BNTXBioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer Mainz, Germany
BioNTech SE has appointed Annemarie Hanekamp as the Chief Commercial Officer, effective July 1, 2024. Hanekamp, who previously worked at Novartis AG, will succeed Sean Marett and is tasked with driving global commercialization strategies, particularly in preparation for BioNTech's first oncology product launch slated for 2026. Her experience includes leading successful product launches and a strong focus on innovative oncology treatments, which aligns with BioNTech's strategic growth goals through to 2030. The appointment is seen as a move to enhance the company's marketing and operational capabilities in the biopharmaceutical market.
Read more →BNTXBIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
Bernstein Liebhard LLP has alerted investors regarding a class action lawsuit against BioNTech SE, which pertains to alleged securities law violations committed between March 30, 2022, and October 13, 2023. The lawsuit claims that BioNTech made materially false statements regarding the demand for its COVID-19 vaccine, Comirnaty, leading to significant inventory write-offs. Following the announcement of these write-offs, BioNTech's share price fell by 6.38%. Investors are reminded of the upcoming deadline to file a lead plaintiff motion by March 12, 2024.
Read more →BNTXBioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
Read more →BNTXBIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against BioNTech SE, with allegations of materially false and misleading statements made during the Class Period from March 30, 2022, to October 13, 2023. The complaint claims that BioNTech overinflated demand for its COVID-19 vaccine Comirnaty and failed to disclose excess inventory of raw materials. As a result, the company faces potential financial implications, including significant inventory write-offs. Investors are encouraged to take action before the March 12, 2024 deadline to participate in the lawsuit.
Read more →BNTXBioNTech Announces Planned Retirement of Sean Marett
BioNTech Announces Planned Retirement of Sean Marett
Read more →BNTXBioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
Read more →BNTXBioNTech SE investors: Please contact the Portnoy Law Firm to recover your losses; March 12, 2024 deadline
A lawsuit has been initiated by the Portnoy Law Firm on behalf of investors who purchased BioNTech SE securities between March 30, 2022, and October 13, 2023. The allegations suggest that BioNTech did not transparently communicate issues related to the demand for their COVID-19 vaccine, Comirnaty, and had excess inventory that was mismanaged. Investors are invited to contact the law firm to explore options for recovering potential losses, as the case claims that misleading optimistic statements were made regarding the company's performance and future prospects.
Read more →BNTXBioNTech SE Sued for Securities Law Violations - Contact The Gross Law Firm Before March 12, 2024 to Discuss Your Rights – BNTX
BioNTech SE is being sued for securities law violations related to its COVID-19 vaccine, Comirnaty. The lawsuit alleges that the company misrepresented the demand for the vaccine and did not disclose accumulated excess inventory, possibly leading to significant financial implications. Shareholders who purchased BNTX shares during a specific class period are urged to register for the class action. The deadline for lead plaintiff applications is March 12, 2024.
Read more →BNTXBIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options
BioNTech SE is currently under investigation by Faruqi & Faruqi, LLP for potential securities violations regarding its communications related to the COVID-19 vaccine, Comirnaty. The law firm has encouraged investors who lost more than $100,000 between specific dates to contact them about pursuing legal options. Allegations include overstating demand for the vaccine and failing to disclose excess inventory, all of which may result in significant financial repercussions for the company. This development comes after BioNTech has issued reports indicating a substantial drop in expected revenues.
Read more →BNTXBIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential securities claims against BioNTech SE following allegations of false statements related to the demand for its COVID-19 vaccine, Comirnaty. The firm is encouraging investors who lost over $100,000 from March 30, 2022, to October 13, 2023, to seek legal options before the deadline of March 12, 2024. BioNTech has reportedly faced challenges due to inventory write-offs and declining vaccination rates, causing its stock price to drop significantly in recent months. Investors are urged to contact the firm for more information.
Read more →BNTXBioNTech SE investors: Please contact the Portnoy Law Firm to recover your losses; March 12, 2024 deadline.
The Portnoy Law Firm has announced a lawsuit on behalf of BioNTech SE investors who bought shares between March 30, 2022, and October 13, 2023. The lawsuit alleges that BioNTech misled investors regarding the demand for its COVID-19 vaccine, Comirnaty, and that the company overstocked raw materials and doses not aligned with current market needs. As a result, BioNTech may face significant charges related to excess inventory write-offs. Investors are encouraged to contact the law firm for potential recovery options.
Read more →BNTXBIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential claims against BioNTech SE due to alleged violations of federal securities laws, particularly regarding misleading statements about demand for its COVID-19 vaccine, Comirnaty. Investors suffering losses exceeding $100,000 between March 30, 2022, and October 13, 2023, are encouraged to contact the firm. The investigation follows announcements of significant inventory write-offs and decreased revenue forecasts linked to low vaccination rates. Legal deadlines for filing claims are approaching, with important investor actions recommended.
Read more →BNTXBioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Read more →BNTXBioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
Read more →BNTXBioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
Read more →BNTXBioNTech SE (BNTX) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against BioNTech SE
Robbins LLP has announced a class action lawsuit against BioNTech SE on behalf of shareholders who acquired stock between March 30, 2022, and October 13, 2023. The complaint alleges that the company misrepresented the demand for its COVID-19 vaccine, Comirnaty, and failed to disclose significant inventory issues. Following the announcement of potential inventory write-offs amounting to €0.9 billion due to excess raw materials and doses, BioNTech's share price declined by 6.38%. Shareholders looking to participate in the class action must file their lead plaintiff papers by March 12, 2024.
Read more →BNTXBIONTECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against BioNTech SE on behalf of investors who purchased its securities during a specified period. The lawsuit claims that BioNTech made materially false statements regarding its business operations, particularly overstating demand for its COVID-19 vaccine, Comirnaty. Investors are encouraged to participate in the action and can apply to be lead plaintiff until March 12, 2024. This legal challenge raises concerns about potential financial repercussions for the company.
Read more →BNTXBIONTECH SE SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX)
BioNTech SE is facing a securities class action lawsuit filed by Bernstein Liebhard LLP on behalf of investors who purchased shares between March 30, 2022, and October 13, 2023. The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that the company made materially false statements and failed to disclose risks related to its COVID-19 vaccine, Comirnaty. As a result, BioNTech is at risk of recognizing significant inventory write-offs and charges. The lawsuit comes in the wake of a press release revealing a forecasted €0.9 billion in related inventory losses, which led to a notable drop in the company's share price.
Read more →BNTXBioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
Read more →BNTXBioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
Read more →BNTXBioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
Read more →BNTXBioNTech to Inaugurate First African Site on December 18, 2023
BioNTech to Inaugurate First African Site on December 18, 2023
Read more →BNTXBioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
Read more →BNTXPfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Read more →BNTXBioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
Read more →BNTXBioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Read more →BNTXBioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
Read more →BNTXUpdate Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
Read more →BNTXBioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
Read more →BNTXPfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Read more →BNTXBioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
Read more →BNTXBioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
BioNTech has appointed James Ryan, Ph.D., as Chief Legal Officer effective September 1, 2023, strengthening its Management Board. Ryan brings nearly 20 years of legal expertise, having previously served as the company’s General Counsel. He will oversee corporate legal strategy and operations as BioNTech advances its pipeline candidates into later clinical stages and prepares for potential market launches. This leadership expansion aligns with BioNTech's goals of improving global health through innovative biopharmaceutical solutions.
Read more →BNTXBioNTech Announces Second Quarter 2023 Financial Results and Corporate Update Significant pipeline advancement highlighted by the initiation of BNT316 ONC-392 Phase 3 pivotal trial and multiple trials planned to start ac
BioNTech SE has announced its second quarter and first half 2023 financial results, highlighting key advancements in its oncology pipeline. The company has initiated a Phase 3 trial for BNT316 ONC-392 and is preparing to launch a new variant-adapted COVID-19 vaccine, pending regulatory approval. Despite these advancements, BioNTech reported a net loss of 190.4 million in Q2, significantly down from profit last year, attributing some financial downturn to write-offs by its partner Pfizer. The outlook for vaccine revenues remains uncertain, prompting the company to adjust its expense guidance while aiming to maintain strategic growth.
Read more →BNTXBioNTech Completes Acquisition of InstaDeep Acquisition aims to strengthen BioNTech's pioneering position in the field of AI-powered drug discovery, design and development InstaDeep to operate as London based subsidiary
BioNTech SE announced the completion of its acquisition of InstaDeep Ltd., a leader in artificial intelligence and machine learning. This strategic move aims to bolster BioNTech's capabilities in AI-powered drug discovery and the development of next-generation therapies. InstaDeep will operate as a subsidiary in London and will continue to offer services beyond BioNTech-focused projects. The acquisition adds around 290 personnel with expertise in AI and data science to BioNTech's portfolio, enhancing its innovative capabilities in combating diseases.
Read more →BNTXBioNTech Completes Acquisition of InstaDeep
BioNTech Completes Acquisition of InstaDeep
Read more →BNTXBioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
Read more →BNTXBioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Read more →BNTXBioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
Read more →BNTXPfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission NEW YORK and MAINZ, GERMANY, MAY 26, 2023 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today announced they h
Pfizer Inc. and BioNTech SE announced an amendment to their COVID-19 vaccine supply agreement with the European Commission. This updated contract allows for rephasing of vaccine deliveries through 2026 while maintaining access to future vaccines for EU member states. The agreement reflects the companies' ongoing collaboration to address public health needs amid the pandemic. Vaccination efforts in Europe have reportedly saved millions of lives and facilitated economic stabilization during challenging times.
Read more →BNTXChanges in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023 Baroness Nicola Blackwood newly appointed to Supervisory Board Michael Motschmann and Ulrich Wandschneider, Ph.D. re
BioNTech SE announced changes to its Supervisory Board following the Annual General Meeting held on May 25, 2023. Baroness Nicola Blackwood was appointed to the board with overwhelming shareholder support, succeeding Prof. Christoph Huber, who is now a member of the scientific advisory board. Michael Motschmann and Ulrich Wandschneider were both reappointed for another term. All other resolutions from the AGM were passed, indicating strong shareholder confidence in the company's direction.
Read more →BNTXBioNTech Announces First Quarter 2023 Financial Results and Corporate Update COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates an
BioNTech SE reported its first quarter 2023 financial results, revealing revenues of $1.3 billion and a net profit of $0.5 billion. The company is focused on advancing its clinical-stage pipeline in oncology and infectious diseases. A Phase 3 trial for the anti-CTLA-4 antibody BNT316 is planned in NSCLC patients, while they continue to develop next-gen COVID-19 vaccines amidst declining revenues from the current vaccine franchise. BioNTech is also starting a First-in-Human trial for an mRNA-based tuberculosis vaccine, expanding its portfolio significantly.
Read more →BNTXBioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
Read more →BNTXthe German language invitation is decisive BioNTech SE Mainz WKN A0V9BC ISIN DE000A0V9BC4 Invitation to the Annual General Meeting 2023 Unique identifier of the event 327fbe3ffdceed118145005056888925 Dear Sir or Madam 1
BioNTech SE is inviting shareholders to its Annual General Meeting on May 25, 2023, where key financial reports and resolutions will be presented. The meeting will take place at the company's offices in Mainz, Germany, with provisions for remote access for American Depositary Shares holders. The agenda includes the approval of financial statements and the ratification of actions taken by the Management and Supervisory Boards. A new resolution on the appropriation of balance sheet profit for the 2021 financial year is also slated for discussion.
Read more →BNTXBioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
Read more →BNTXBioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
Read more →BNTXDocument BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Expanded and advanced oncology pipeline to 20 programs in 24 ongoing clinical trials including five ongoing randomized
BioNTech has reported its financial results for the fourth quarter and full year of 2022, showing total revenues of $17.3 billion but a decline from the previous year. The company has expanded its oncology pipeline to 20 programs and initiated a Phase 1 trial for four mRNA vaccine candidates in infectious diseases. While revenue from COVID-19 vaccine sales has been strong, challenges such as reduced demand and increased costs are noted. BioNTech expects to continue its investment in R&D and evolve its commercial capabilities in oncology.
Read more →BNTXBioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications BioNTech to receive exclusive worldwide license from OncoC4 to develop an
BioNTech and OncoC4 have entered a strategic collaboration to develop the anti-CTLA-4 monoclonal antibody, ONC-392, aimed at treating various solid tumors. BioNTech will obtain exclusive worldwide rights for this candidate, which is designed to improve immune response while minimizing adverse effects. The collaboration includes shared development costs and significant upfront payments to OncoC4. A Phase 3 trial is anticipated to begin in 2023, focusing on immunotherapy-resistant non-small cell lung cancer.
Read more →BNTXPfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years NEW YORK and MAINZ, GERMANY
Pfizer and BioNTech have received emergency use authorization (EUA) from the FDA for their Omicron BA.4 BA.5-adapted bivalent COVID-19 vaccine for children aged 6 months to 4 years. This booster dose, which can be administered at least two months post-primary vaccination, shows improved antibody responses compared to the original vaccine. The companies are also seeking similar authorizations worldwide, while emphasizing the unique safety profile and efficacy of the new bivalent vaccine.
Read more →BNTXBioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
Read more →BNTXPfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years NEW YORK and MAINZ, GERMANY
Pfizer and BioNTech have submitted an application for Emergency Use Authorization (EUA) from the FDA for a booster dose of their Omicron BA.4 BA.5-adapted bivalent COVID-19 vaccine aimed at children aged 6 months to under 5 years. The booster aims to enhance immunity against newer circulating Omicron variants. Preliminary data from their studies indicate the booster elicits a higher neutralizing response compared to three doses of the original vaccine while maintaining a similar safety profile. The companies also plan to seek regulatory approval in other regions, including the EU.
Read more →BNTXBioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
Read more →BNTXPfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster NEW YORK and MAI
Pfizer and BioNTech have submitted a supplemental Biologics License Application to the U.S. FDA for their Omicron BA.4 BA.5-adapted bivalent COVID-19 vaccine, aimed at individuals aged 12 and older. This vaccine, if approved, will allow for its use as both a primary series and booster. The submission is supported by data showing that the bivalent vaccine induces a superior neutralizing antibody response against newer Omicron variants, especially in participants aged 55 and older. The companies are also looking to secure approval in the EU for broader use in various age groups.
Read more →BNTXBioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
Read more →BNTXBioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development Acquisition to enable creation of a fully integrated, enterprise-wide capability to discov
BioNTech has announced its acquisition of InstaDeep to strengthen its capabilities in AI-powered drug discovery and development. The transaction involves an upfront payment of approximately $362 million and is set to add around 240 skilled professionals to BioNTech's workforce. This acquisition follows a multi-year strategic partnership that has included numerous joint projects in AI and machine learning. The deal is expected to close in the first half of 2023, pending regulatory approval, and will position BioNTech to enhance its immunotherapy projects leveraging advanced AI technologies.
Read more →BNTXBioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
Read more →BNTXBioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
Read more →BNTXBioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
Read more →BNTXBioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China Approximately 11,500 of the companies' mRNA-based COVID-19 vaccine doses arrived on the Chinese Mainland to enable v
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China Approximately 11,500 of the companies' mRNA-based COVID-19 vaccine doses arrived on the Chinese Mainland to enable vaccination campaign for German expatriates Vaccines expect
Read more →BNTXUpdate on First BioNTainer for African-based mRNA Manufacturing Facility
Update on First BioNTainer for African-based mRNA Manufacturing Facility
Read more →BNTXBioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
Read more →BNTXPfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza NEW YORK, USA and MAINZ, GERMANY, December 9, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX, "BioNTech") today announc
Read more →BNTXDisclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596 2014 of the European Parliament and the Council of
Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596 2014 of the European Parliament and the Council of April 16, 2014 and Art. 2(1) of Delegated Regulation (EU) 2016 1052 of the European Commission of March 8, 2016 Mainz, Germany, Decembe
Read more →BNTXPfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years Bivalent vaccine authorized as third 3- g dose in the three-dose primary
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years Bivalent vaccine authorized as third 3- g dose in the three-dose primary series Consistent COVID-19 hospitalization rates in this a
Read more →BNTXPfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years NEW YORK, USA and MAINZ, GERMANY, December 5, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX
Read more →BNTXBioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates The companies enter a multi-target research collaboration to develop multiple small
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and
Read more →BNTXPfizer and BioNTech Report New Data on Omicron BA.4 BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages One month after a 30- g booster dose of the Omicron BA.4 BA.5-
Pfizer and BioNTech Report New Data on Omicron BA.4 BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages One month after a 30- g booster dose of the Omicron BA.4 BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody ti
Read more →BNTXPfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection NEW YORK, USA and MAINZ, GERMANY, November 16, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (N
Read more →BNTXBioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union NEW YORK, USA and MAINZ, GERMANY, November 10, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Na
Read more →BNTXBioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
Read more →BNTXUnaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed Consolidated Statements of Comprehensive Income 4 Interim Condensed Consolidat
Quarterly Report of BioNTech SE for the Three And Nine Months Ended September 30, 2022 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed Consolidated Statements of Comprehensive Income
Read more →BNTXPfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4 BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine Bivalent booster el
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4 BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine Bivalent booster elicited approximately 4-fold higher neutralizing antibody ti
Read more →BNTXBioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY in Children 6 Months to less than 5 Years in the European Union NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY in Children 6 Months to less than 5 Years in the European Union NEW YORK, USA and MAINZ, GERMANY, October 19, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX, "BioNTech") today announced that th
Read more →BNTXPfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4 BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older Sera collected from participants 7 days after administration of a 30- g
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4 BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older Sera collected from participants 7 days after administration of a 30- g booster dose of the Omicron BA.4 BA.5-adapted bivalent COV
Read more →BNTXPfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age NEW YORK, USA and MAINZ, GERMANY, October 12, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BN
Read more →BNTXBioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
Read more →BNTXPfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age NEW YORK, USA and MAINZ, GERMANY, September 26, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY Conditional Marketing Authorization to Full Marketing Authorization in the European Union Standard marketing authorization recommendation appl
Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY Conditional Marketing Authorization to Full Marketing Authorization in the European Union Standard marketing authorization recommendation applies to all indications and formulations in the European Uni
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union CHMP recommendation based on favorable data from Omicron-adapted vaccines The Omicron BA
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union CHMP recommendation based on favorable data from Omicron-adapted vaccines The Omicron BA.4 BA.5 bivalent COVID-19 booster vaccine combines 15- g o
Read more →BNTXBioNTech Presents Encouraging Phase 1 2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageabl
BioNTech Presents Encouraging Phase 1 2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive
Read more →BNTXBioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines
BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2 3 t
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2 3 trial of the Omicron BA.1-adapted bivalent vaccine The Omic
Read more →BNTXPfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older Authorization based on clinical, pre-clinical and manufacturing data
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccines Pfizer-BioNTech Omic
Read more →BNTXPfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4 BA.5 Adapted Bivalent Vaccine Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4 BA.5 Adapted Bivalent Vaccine Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4 5-adapted biv
Read more →BNTXStatement on Patent Infringement Lawsuit Filed by Moderna BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY infringes certain Moderna patents. BioNTech's work is original, an
Statement on Patent Infringement Lawsuit Filed by Moderna BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY infringes certain Moderna patents. BioNTech's work is original, and we will vigorously defend against all allegations of pate
Read more →BNTXPfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showe
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children ages 6 months throu
Read more →BNTXPfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Data support request for Emergency Use Authorization of a 30- g booster dose of an
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4 BA.5-Adapted Bivalent COVID-19 Vaccine Data support request for Emergency Use Authorization of a 30- g booster dose of an Omicron BA.4 BA.5-adapted bivalent COVID-19 vaccine for in
Read more →BNTXBioNTech Announces Second Quarter Financial Results and Corporate Update
BioNTech Announces Second Quarter Financial Results and Corporate Update
Read more →BNTXBioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
Read more →BNTXDocument BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates Collaboration expands to include development of monospecific antibody candidates to address m
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab's pro
Read more →BNTXPfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design NEW YORK, USA and MAINZ, GERMANY, July 27, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX, "BioNTech") today a
Read more →BNTXBioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022
BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022
Read more →BNTXPfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate NEW YORK, USA and MAINZ, GERMANY, July 19, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX, "BioNTech") today announced they have complet
Read more →BNTXPfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY NEW YORK, USA and MAINZ, GERMANY, July 8, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX, "BioNTech") today that the companies ha
Read more →BNTXPfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY For Adolescents 12 through 15 Years of Age COMIRNATY is the first and only COVID-19 vaccine to be granted FDA approval for adolescents 12
Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY For Adolescents 12 through 15 Years of Age COMIRNATY is the first and only COVID-19 vaccine to be granted FDA approval for adolescents 12 years and older, following emergency use authorization in
Read more →BNTXStatement on Patent Infringement Lawsuit in Germany BioNTech values and respects valid intellectual property rights. BioNTech's work is original, and we will vigorously defend it against all allegations of patent infring
Statement on Patent Infringement Lawsuit in Germany BioNTech values and respects valid intellectual property rights. BioNTech's work is original, and we will vigorously defend it against all allegations of patent infringement. However, we are aware that it is not unusual that ot
Read more →BNTXPfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine 105 million 30 g, 10 g and 3 g doses to be delivered into Q4 2022, with an option for the U.S. Government to
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine 105 million 30 g, 10 g and 3 g doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK, USA
Read more →BNTXPfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron B
Read more →BNTXBioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
Read more →BNTXBioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer First BioNTech product candidate to receive priority medicines (PRIME) desi
BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regul
Read more →BNTXBioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations
BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations
Read more →BNTXPfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age In a Phase 2 3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age In a Phase 2 3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3- g doses had favorable safety p
Read more →BNTXPfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine NEW YORK, USA and MAINZ, GERMANY, June 15, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX, "BioNTech") today announced the European
Read more →BNTXBioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa
BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa
Read more →BNTXPositive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO Preliminary analysis of data from an ongoing investigator-initiated, si
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO Preliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genente
Read more →BNTXVoting Results from BioNTech's Annual General Meeting 2022 Shareholders reappointed Helmut Jeggle as Chairman of the Supervisory Board Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will complement the existing S
Voting Results from BioNTech's Annual General Meeting 2022 Shareholders reappointed Helmut Jeggle as Chairman of the Supervisory Board Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will complement the existing Supervisory Board to reflect company growth Shareholders f
Read more →BNTXPfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose Based on topline data, three doses of the Pfizer-
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria r
Read more →BNTXPfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age EUA is based on data that show children 5 through 11 years of age had a robust
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age EUA is based on data that show children 5 through 11 years of age had a robust immune response with a favorable safety profile following
Read more →BNTXPfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission NEW YORK, USA and MAINZ, GERMANY, May 16, 2022 - Pfizer Inc. (NYSE PFE, "Pfizer") and BioNTech SE (Nasdaq BNTX, "BioNTech") announced they have reached an agreement with the European
Read more →BNTXBioNTech Announces First Quarter Financial Results and Corporate Update
BioNTech Announces First Quarter Financial Results and Corporate Update
Read more →BNTXBioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022
BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022
Read more →BNTXPfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age NEW YORK, USA and MAINZ, GERMANY, April 26, 2022 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today submitted an applic
Read more →BNTXPfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age Data from a subanalysis of 30 sera from a Phase 2 3 clinical t
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age Data from a subanalysis of 30 sera from a Phase 2 3 clinical trial of children 5 through 11 years of age show a 36-fold i
Read more →BNTXBioNTech Presents Positive Preliminary Phase 1 2 Data for First-in-Class CAR-T Program BNT211 at AACR BNT211 combines two innovative approaches in one regimen, an autologous CAR-T cell therapy targeting the oncofetal ant
BioNTech Presents Positive Preliminary Phase 1 2 Data for First-in-Class CAR-T Program BNT211 at AACR BNT211 combines two innovative approaches in one regimen, an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amp
Read more →BNTXBioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
Read more →BNTXBioNTech Granted Pandemic Preparedness Contract by German Federal Ministry of Health
BioNTech Granted Pandemic Preparedness Contract by German Federal Ministry of Health
Read more →BNTXB ioNTech Granted Pandemic Preparedness Contract by German Federal Ministry of Health Mainz, Germany
BioNTech Granted Pandemic Preparedness Contract by German Federal Ministry of Health Mainz, Germany, April 8, 2022 - BioNTech SE (Nasdaq BNTX, "BioNTech") announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the Federal Republic
Read more →BNTXBioNTech Announces ADS Repurchase Program
BioNTech Announces ADS Repurchase Program
Read more →BNTXBioNTech Announces ADS Repurchase Program MAINZ, GERMANY, MARCH 31, 2022 - "BioNTech" or the "Company") today announced that it has entered into a share repurchase program (the "Program"), pursuant to which the Company m
BioNTech Announces ADS Repurchase Program MAINZ, GERMANY, MARCH 31, 2022 - "BioNTech" or the "Company") today announced that it has entered into a share repurchase program (the "Program"), pursuant to which the Company may purchase American depositary shares (ADSs) in the amount
Read more →BNTXBioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Read more →BNTXPfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older FDA also authorizes second booster dose for individuals 12 years of
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older FDA also authorizes second booster dose for individuals 12 years of age and older who have certain kinds of immunocompromise S
Read more →BNTXBioNTech to Report Full Year and Fourth Quarter 2021 Financial Results and Operational Update on March 30, 2022
BioNTech to Report Full Year and Fourth Quarter 2021 Financial Results and Operational Update on March 30, 2022
Read more →BNTXPfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults Submission based on real-world safety and efficacy data from Israel Data showed rat
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of
Read more →BNTXBioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo (cemiplimab) Combination in NSCLC BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixV
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo (cemiplimab) Combination in NSCLC BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the tre
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union NEW YORK, USA and MAINZ, GERMANY, February 24, 2022 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today announced that the Comm
Read more →BNTXBioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer Collaboration leverages BioNTech's multi-platform immunotherapy capabilities and Medigene's T cell receptor (T
BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer Collaboration leverages BioNTech's multi-platform immunotherapy capabilities and Medigene's T cell receptor (TCR) discovery platform to discover and develop innovative
Read more →BNTXBioNTech Introduces First Modular mRNA Manufacturing Facility to Promote Scalable Vaccine Production in Africa Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed b
BioNTech Introduces First Modular mRNA Manufacturing Facility to Promote Scalable Vaccine Production in Africa Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech Presidents of Ghana, Rwanda, Senegal, the Dire
Read more →BNTXBioNTech to Join High-level Meeting with Partners in Marburg and to Hold Press Conference to Provide an Update on Sustainable Vaccine Manufacturing in Africa
BioNTech to Join High-level Meeting with Partners in Marburg and to Hold Press Conference to Provide an Update on Sustainable Vaccine Manufacturing in Africa
Read more →BNTXPfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age NEW YORK, USA and MAINZ, GERMANY, February 11, 2022 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today announc
Read more →BNTXThe curious case of the BioNTech priority review voucher Zachary Brennan
The curious case of the BioNTech priority review voucher Earlier this week, the FDA fully approved Moderna's Covid-19 vaccine, and with that approval, the company was awarded what is almost certainly a lucrative priority review voucher. The vouchers can be used for a priority r
Read more →BNTXPfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA With pediatric COVID-19 cases surpassi
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies
Read more →BNTXPfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary s
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK, USA and MAINZ, GERM
Read more →BNTXPfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant NEW YORK, USA and MAINZ, GERMANY, January 24, 2022 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today announced the publ
Read more →BNTXBioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants Early Warning System combines Spike protein structural modeling with artificial intelligence
BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants,
Read more →BNTXTitelmasterformat durch Klicken bearbeiten This slide presentation includes forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
1 January 11th 2022 J.P. MORGAN HEALTHCARE CONFERENCE Exhibit 99.1 2 Titelmasterformat durch Klicken bearbeiten This slide presentation includes forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigati
Read more →BNTXBioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies Collaboration leverages BioNTech's proprietary multimodal immunotherapy expertise with Crescendo's propri
BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies Collaboration leverages BioNTech's proprietary multimodal immunotherapy expertise with Crescendo's proprietary Humabody VH platform to develop precision immunothera
Read more →BNTXPfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for sh
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease tha
Read more →BNTXPfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older First emergency use authorization in the United States for a COVID-19 vaccine booster
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older First emergency use authorization in the United States for a COVID-19 vaccine booster in adolescents 12 through 15 years of age Today's FDA act
Read more →BNTXBioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference
BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference
Read more →BNTXPfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY to Help Meet Continued Need for Vaccine Supply European Comission exercise part of its option for over 200 million additio
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY to Help Meet Continued Need for Vaccine Supply European Comission exercise part of its option for over 200 million additional doses to be delivered in 2022 These doses are in addit
Read more →BNTXPfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine NEW YORK, USA and MAINZ, GERMANY, December 17, 2021 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S
Read more →BNTXPfizer And BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY in Adolescents 12 Through 15 Years of Age NEW YORK, USA and MAINZ, GERMANY
Pfizer And BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY in Adolescents 12 Through 15 Years of Age NEW YORK, USA and MAINZ, GERMANY, December 17, 2021 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today announced they hav
Read more →BNTXPfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older First emergency use authorization in the United States for a COVID-19 vaccine booster in ind
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older NEW YORK, USA and MAINZ, GERMA
Read more →BNTXPfizer and BioNTech Provide Update on Omicron Variant Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage), while two dose
Pfizer and BioNTech Provide Update on Omicron Variant Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage), while two doses show significantly reduced neutralization titers Data in
Read more →BNTXBioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant
BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant
Read more →BNTXK 1 ex991bnt_presseventxupda.htm 6-K ex991bnt_presseventxupda OMICRON VARIANT (B.1.1.529)
OMICRON VARIANT (B.1.1.529) December 8, 2021 Update 1 This press release contains "forward-looking statements" of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, stateme
Read more →BNTXOmicron Unlikely to Cause Severe Illness in Vaccinated People, BioNTech Founder Says By Bojan Pancevski Variant could lead to more infections but vaccinated people likely remain protected from severe disease, Ugur Sahin
Omicron Unlikely to Cause Severe Illness in Vaccinated People, BioNTech Founder Says Variant could lead to more infections but vaccinated people likely remain protected from severe disease, Ugur Sahin says. BERLIN-The Omicron variant of the coronavirus could lead to more infect
Read more →BNTXPfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY in Children 5 to under 12 Years of Age in the European Union NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY in Children 5 to under 12 Years of Age in the European Union NEW YORK, USA and MAINZ, GERMANY, November 26, 2021 - Pfizer Inc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) today announced that the Committee for Medicina
Read more →BNTXNOV 26, 2021 - 13 24 BioNTech will take two weeks to assess vaccine against latest Covid variant Hannah Kuchler BioNTech will know in two weeks whether the vaccine it developed with Pfizer will work against the new B.1.1
NOV 26, 2021 - 13 24 BioNTech will take two weeks to assess vaccine against latest Covid variant BioNTech will know in two weeks whether the vaccine it developed with Pfizer will work against the new B.1.1.529 variant of Covid that has emerged in southern Africa. The German co
Read more →BNTXFollow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in long
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identifie
Read more →BNTXPFIZER AND BIONTECH RECEIVE EXPANDED U.S. FDA EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE BOOSTER TO INCLUDE INDIVIDUALS 18 AND OLDER Expanded authorization allows more Americans to receive a booster dose to help pre
PFIZER AND BIONTECH RECEIVE EXPANDED U.S. FDA EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE BOOSTER TO INCLUDE INDIVIDUALS 18 AND OLDER Expanded authorization allows more Americans to receive a booster dose to help preserve a high-level of protection against COVID-19 NEW YORK
Read more →BNTXBioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma BERLIN, Germany, November 19, 2021 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq BNTX, "BioNTech" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) grante
Read more →BNTXPfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older Submission is based on efficacy and safety data from a Phase 3 ra
Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older Submission is based on efficacy and safety data from a Phase 3 randomized, controlled trial with more than 10,000 participan
Read more →BNTXBioNTech SE Quarterly Report for the Three and Nine Months Ended
Quarterly Report for the Three and Nine Months Ended September 30, 2021 Quarterly Report for the Three and Nine Months Ended September 30, 2021 Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed C
Read more →BNTXBioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
Read more →BNTXBioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting
BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting
Read more →BNTXPfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Ye
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years Emergency Use Authorization (EUA) is supported by clini
Read more →BNTXPFIZER AND BIONTECH TO PROVIDE U.S. GOVERNMENT AN ADDITIONAL 50 MILLION PEDIATRIC DOSES OF COVID-19 VACCINE TO SUPPORT FURTHER PREPAREDNESS FOR FUTURE NEEDS Doses expected to be delivered by April 2022 NEW YORK, USA and
PFIZER AND BIONTECH TO PROVIDE U.S. GOVERNMENT AN ADDITIONAL 50 MILLION PEDIATRIC DOSES OF COVID-19 VACCINE TO SUPPORT FURTHER PREPAREDNESS FOR FUTURE NEEDS Doses expected to be delivered by April 2022 NEW YORK, USA and MAINZ, GERMANY, October 28, 2021 - Pfizer Inc. (NYSE PFE)
Read more →BNTXBioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021
BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021
Read more →BNTXFDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
Read more →BNTXBioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022 BioNTech signs Memorandum of Understanding with Rwandan Government and the Institut Pasteur de Dakar. Constructi
BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022 BioNTech signs Memorandum of Understanding with Rwandan Government and the Institut Pasteur de Dakar. Construction of the first mRNA manufacturing facility in Africa is pl
Read more →BNTXPfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Read more →BNTXPFIZER ANDBIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A COVID-19 VACCINE BOOSTER First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 9
PFIZER ANDBIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A COVID-19 VACCINE BOOSTER First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the pre
Read more →BNTXNew Formulation of COMIRNATY Receives Positive Opinion from CHMP NEW YORK, USA and MAINZ, GERMANY
New Formulation of COMIRNATY Receives Positive Opinion from CHMP NEW YORK, USA and MAINZ, GERMANY, October 18, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency s (EMA) Committee for Human Medicinal Products (CHMP)
Read more →BNTXPfizer and BioNTech Submitted Data to EMA for the Vaccination of Children 5 to less than 12 Years of Age NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Submitted Data to EMA for the Vaccination of Children 5 to less than 12 Years of Age NEW YORK, USA and MAINZ, GERMANY, October 15, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they submitted data supporting the vaccinatio
Read more →BNTXPfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union NEW YORK, USA and MAINZ, GERMANY, October 4, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use
Read more →BNTXBioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
Read more →BNTXBioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients Second Phase 2 trial initiated from BioNTech's propri
BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients MAINZ, Germany, October 1, 2021 (GLOBE NEWSWIRE) - BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), anno
Read more →BNTXPFIZER AND BIONTECH SUBMIT INITIAL DATA TO U.S. FDA FROM PIVOTAL TRIAL OF COVID-19 VACCINE IN CHILDREN 5 TO 12 YEARS OF AGE Formal submission to request Emergency Use Authorization to follow in the coming weeks NEW YORK,
PFIZER AND BIONTECH SUBMIT INITIAL DATA TO U.S. FDA FROM PIVOTAL TRIAL OF COVID-19 VACCINE IN CHILDREN 5 TO <12 YEARS OF AGE Formal submission to request Emergency Use Authorization to follow in the coming weeks NEW YORK, USA and MAINZ, GERMANY, September 28, 2021 - Pfizer Inc.
Read more →BNTXP fizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries Expanded agreement brings the total number of COVID-1
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries NEW YORK, USA and MAINZ, GERMANY, September 22, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) tod
Read more →BNTXPfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
Read more →BNTXPfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster Emergency Use Authorization (EUA) granted for individuals 65 years of age and older, and individuals ages 18 through 64
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster NEW YORK, USA and MAINZ, GERMANY, September 22, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has
Read more →BNTXPfizer and BioNTech Submit a Variation to EMA with the Data in Support of a Booster Dose of COMIRNATY NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Submit a Variation to EMA with the Data in Support of a Booster Dose of COMIRNATY NEW YORK, USA and MAINZ, GERMANY, September 20, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from a Phase 2/3 trial showing a favorable
Read more →BNTXPfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Read more →BNTXFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
Read more →BNTXJoint Communiqu : BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply
Joint Communiqu : BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply BERLIN, Germany, August 27, 2021 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") agreed today to evaluate the establishm
Read more →BNTXPfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
Read more →BNTXPfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
Read more →BNTXPfizer-BioNTech COVID-19 Vaccine COMIRNATY Receives Full U.S. FDA Approval for Individuals 16 Years and Older COMIRNATY is the first COVID-19 vaccine to be granted FDA approval Approval is based on a comprehensive submis
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY Receives Full U.S. FDA Approval for Individuals 16 Years and Older NEW YORK, USA and MAINZ, GERMANY, August 23, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FD
Read more →BNTXPfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY in Individuals 16 and Older New Phase 3 data show booster (third) dose of COMIRNATY
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY in Individuals 16 and Older NEW YORK, USA and MAINZ, GERMANY, August 23, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today an
Read more →BNTXPfizer and BioNTech Announce Collaboration with Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America NEW YORK, USA and MAINZ, GERMANY
Pfizer and BioNTech Announce Collaboration with Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America NEW YORK, USA and MAINZ, GERMANY, August 23, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent
Read more →BNTXPFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vacci
PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE NEW YORK, USA and MAINZ, GERMANY, August 16, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the
Read more →BNTXBioNTech SE Quarterly Report for the Three and Six Months Ended
Quarterly Report for the Three and Six Months Ended June 30, 2021 Quarterly Report for the Three and Six Months Ended June 30, 2021 Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed Consolidated
Read more →BNTXBioNTech Announces Second Quarter 2021 Financial Results and Corporate Update
BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update
Read more →BNTXBioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
Read more →BNTXBioNTech to Report Second Quarter Financial Results and Operational Update on August 9, 2021
BioNTech to Report Second Quarter Financial Results and Operational Update on August 9, 2021
Read more →BNTXBioNTech provides update on plans to develop sustainable solutions to address infectious diseases on the African continent BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation
BioNTech provides update on plans to develop sustainable solutions to address infectious diseases on the African continent MAINZ, Germany, July 26, 2021 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced the launch of its Malaria project, which aims to dev
Read more →BNTXPfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S. Dose deliveries for new order expected to occur from Octob
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S. NEW YORK AND MAINZ, GERMANY, July 23, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced t
Read more →BNTXFighting Infectious Diseases on the African Continent
Fighting Infectious Diseases on the African Continent
Read more →BNTXBioNTech Announces Second Quarter 2021 Financial Results and Corporate Update More than one billion doses of BNT162b2 vaccine supplied to more than 100 countries or territories worldwide as of
BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update Conference call and webcast scheduled for August 9, 2021, at 8:00 a.m. ET (2:00 p.m. CET) MAINZ, Germany, August 9, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a
Read more →BNTXPfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa
Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa
Read more →BNTXBioNTech completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland MAINZ, Germany & Santa Monica, USA, 4. August 2021 - BioNTech SE (Nasdaq: BNTX, "BioN
BioNTech completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland MAINZ, Germany & Santa Monica, USA, 4. August 2021 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Kite, a Gilead Company (Nasdaq: GILD, "Kite") t
Read more →BNTXBioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
Read more →BNTXPfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant As part of Pfizer's and BioNTech's continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companie
Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant As part of Pfizer's and BioNTech's continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster st
Read more →BNTXBioNTech SE, Mainz, Germany Annual General Meeting in Munich, Germany, 22 June 2021 Voting results - Overview - Only the German version is binding Agenda Item 2 Approval of the actions of the Management Board - accepted
Voting results - Overview - Only the German version is binding Agenda Item 2Approval of the actions of the Management Board - accepted 139,683,231Number of shares for which valid votes were cast (= 56.71 % of the registered share capital) 139,665,613 Yes votes 99.99 % of the v
Read more →BNTXBioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma First program from BioNTech's fully-owned mRNA cancer vaccine platform FixVac treats patients in a
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma MAINZ, Germany, June 18, 2021 (GLOBE NEWSWIRE) - BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced today that the first patient has been trea
Read more →BNTXFinancial Times, 10.06.2021 BioNTech prepares expansion into Africa alongside EU By Erika Solomon in Berlin and Sam Fleming in Brussels BioNTech is planning a push into Africa, aiming to establish mRNA vaccine production
Financial Times, 10.06.2021 BioNTech prepares expansion into Africa alongside EU By Erika Solomon in Berlin and Sam Fleming in Brussels BioNTech is planning a push into Africa, aiming to establish mRNA vaccine production facilities on the continent as part of a long-term effor
Read more →BNTXPfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations NEW YORK and MAINZ, GERMANY, June 10, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a n
Read more →BNTXPfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents NEW YORK and MAINZ, GERMANY
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents NEW YORK and MAINZ, GERMANY, May 28, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Conditional Marketing Authorization (CMA) for COMIRNA
Read more →BNTXBioNTech Publishes First Sustainability Report and Receives "Prime" Rating by ISS ESG BioNTech is committed to contributing to the UN Sustainable Development Goals (SDGs), particularly the promotion of good health and we
BioNTech Publishes First Sustainability Report and Receives "Prime" Rating by ISS ESG MAINZ, Germany, May 21, 2021 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, ha
Read more →BNTXPfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY New agreement to supply 900 million doses to the European Commission (EC), with option to request up to an additional
Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY NEW YORK AND MAINZ, GERMANY, May 20, 2021-Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900
Read more →BNTXPfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine ISTANBUL, TURKEY and MAINZ, GERMANY
Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine ISTANBUL, TURKEY and MAINZ, GERMANY, May 20, 2021 (GLOBE NEWSWIRE) - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the BioNTech Europe
Read more →BNTXBioNTech Broadens Management Board by Appointing Jens Holstein as CFO MAINZ, GERMANY, 18 May 2021 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), announced today that the Supervisory Board has appointed Jens H
BioNTech Broadens Management Board by Appointing Jens Holstein as CFO MAINZ, GERMANY, 18 May 2021 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), announced today that the Supervisory Board has appointed Jens Holstein to the Management Board as Chief Financial Officer
Read more →BNTXUpdate on Stability of COMIRNATY : More Flexible Storage Conditions On
Update on Stability of COMIRNATY : More Flexible Storage Conditions On May 17, 2021, the European Medicines Agency (EMA) has approved a change to the existing storage conditions. The thawed, undiluted COVID-19 vaccine can be stored at fridge temperatures of 2 C to 8 C for one m
Read more →BNTXPfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 year
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents NEW YORK and MAINZ, GERMANY, May 11, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has expan
Read more →BNTXBioNTech Announces First Quarter 2021 Financial Results and Corporate Update
BioNTech Announces First Quarter 2021 Financial Results and Corporate Update
Read more →BNTXBioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore BioNTech to establish first regional hub in Asia Pacific region in Singapore Planned state-of-the-art man
BioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore MAINZ, GERMANY, 10 May 2021 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today announced plans to expand its global footprint to Asia with the establis
Read more →BNTXBioNTech SE Quarterly Report for the Three Months Ended
Quarterly Report for the Three Months Ended March 31, 2021 Quarterly Report for the Three Months Ended March 31, 2021 Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Financial Position 3 Interim Condensed Consolidated Statements
Read more →BNTXPfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine NEW YORK and MAINZ, GERMANY
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine NEW YORK and MAINZ, GERMANY, May 7, 2021 (GLOBE NEWSWIRE) - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of
Read more →BNTXPFIZER AND BIONTECH TO PROVIDE COVID-19 VACCINE DOSES FOR OLYMPIC ATHLETES AT THE 2020 TOKYO GAMES NEW YORK AND MAINZ, GERMANY, May 6 2021 -Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signi
PFIZER AND BIONTECH TO PROVIDE COVID-19 VACCINE DOSES FOR OLYMPIC ATHLETES AT THE 2020 TOKYO GAMES NEW YORK AND MAINZ, GERMANY, May 6 2021-Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding (MoU) with the Internati
Read more →BNTXBioNTech Announces First Quarter 2021 Financial Results and Corporate Update More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of
BioNTech Announces First Quarter 2021 Financial Results and Corporate Update Conference call and webcast scheduled for May 10, 2021, at 8:00 a.m. ET (2:00 p.m. CET) MAINZ, Germany, May 10, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a next
Read more →BNTXBioNTech to Report First Quarter 2021 Financial Results and Operational Update on May 10, 2021
BioNTech to Report First Quarter 2021 Financial Results and Operational Update on May 10, 2021
Read more →BNTXPfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY in the EU to Adolescents NEW YORK and MAINZ, GERMANY
Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY in the EU to Adolescents NEW YORK and MAINZ, GERMANY, April 30, 2021 (GLOBE NEWSWIRE) - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a vari
Read more →BNTXEurope will reach herd immunity" this summer: BioNTech chief The Hill: Changing America By Adam Barnes
"Europe will reach herd immunity" this summer: BioNTech chief The Hill: Changing America Chief executive Ugur Sahin warned that initial herd immunity would not include children. Ugur Sahin, Co-founder of Biontech SE, makes a speech after receiving the Federal Order Of Merit fr
Read more →BNTXPfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY European Union exercises option under previous agreement to order 100 million additional doses of COMIRNATY , bringing total
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY NEW YORK and MAINZ, GERMANY, April 19, 2021 (GLOBE NEWSWIRE) - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses
Read more →BNTXPfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their COVID-19 Vaccine to Adolescents NEW YORK and MAINZ, GERMANY
Pfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their COVID-19 Vaccine to Adolescents NEW YORK and MAINZ, GERMANY, April 9, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (E
Read more →BNTXPfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study Analysis of 927 confirmed symptomatic
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study New York and Mainz, Germany, April 1, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BN
Read more →BNTXPfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents New York and Mainz, Germany, March 31, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age w
Read more →BNTXBioNTech Announces Full Year 2020 Financial Results and Corporate Update
BioNTech Announces Full Year 2020 Financial Results and Corporate Update
Read more →BNTXto its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC's website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes
EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union New York and Mainz, Germany, March 26, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Medicines Agency (EM
Read more →BNTXEMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union
EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union
Read more →BNTXBioNTech provides Update on Vaccine Production Status at Marburg Manufacturing Site
BioNTech provides Update on Vaccine Production Status at Marburg Manufacturing Site
Read more →BNTXBioNTech Announces Full Year 2020 Financial Results and Corporate Update BNT162b2 vaccine approved or authorized for emergency or temporary use in over 65 countries and regions after successful global Phase 3 trial demon
BioNTech Announces Full Year 2020 Financial Results and Corporate Update Conference call and webcast scheduled for March 30, 2021, at 08:00 a.m. ET (2:00 p.m. CET) MAINZ, Germany, March 30, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a next
Read more →BNTXBioNTech to Report Full Year Financial Results for 2020 and Provide Corporate Update on the Fourth Quarter on March 30, 2021
BioNTech to Report Full Year Financial Results for 2020 and Provide Corporate Update on the Fourth Quarter on March 30, 2021
Read more →BNTXReal-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
Read more →BNTXto its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC's website at www.sec.gov . All information in this press release is as of the date of the release, and BioNTech undertake
Pfizer-BioNTech's COVID-19 Vaccine Arrives in Rwanda First mRNA vaccine doses delivered to the African continent will be used to vaccinate at-risk, front-line healthcare workers NEW YORK and MAINZ, GERMANY, March 3, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)
Read more →BNTXPfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
Read more →BNTXPfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
Read more →BNTXPfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women
Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women
Read more →BNTXIn Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations
In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations
Read more →BNTXPfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
Read more →BNTXPfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine
Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine
Read more →BNTXUpdate on vaccine production at BioNTech’s manufacturing site in Marburg
Update on vaccine production at BioNTech’s manufacturing site in Marburg
Read more →BNTXto its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC's website at www.sec.gov . All information in this statement is as of the date of the release, and BioNTech undertakes no
Update on vaccine production at BioNTech's manufacturing site MAINZ, GERMANY, February 10, 2021 (GLOBE NEWSWIRE) - We started the manufacturing process at the Marburg facility with the execution of the first step: the production of mRNA, which is the active pharmaceutical ingred
Read more →BNTXPfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature
Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature
Read more →BNTXPfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
Read more →BNTXPfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
Read more →BNTXStatement on European Upscaling as well as Impact on Deliveries Pfizer and BioNTech have developed a plan that will allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses in the sec
Statement on European Upscaling as well as Impact on Deliveries Pfizer and BioNTech have developed a plan that will allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses in the second quarter. To accomplish this, certain modifications of p
Read more →BNTXThis slide presentation includes forward-looking statements Forward-looking statements Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the
January 2021 Next Generation Immunotherapy Exhibit 99.1 This slide presentation includes forward-looking statements Forward-looking statements Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the Co
Read more →BNTXAn In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
Read more →BNTXBioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
Read more →BNTXBioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference
BioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference
Read more →BNTXPfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
Read more →BNTXCorrection: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
Read more →BNTXPfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine
Read more →BNTXThis slide presentation includes forward-looking statements Forward-Looking Statements Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the
Update on our COVID-19 vaccine December 22, 2020 Exhibit 99.1 This slide presentation includes forward-looking statements Forward-Looking Statements Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including t
Read more →BNTXPfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
Read more →BNTXPfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
Read more →BNTXBioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program
BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program
Read more →BNTXBioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine
BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine
Read more →BNTXPfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
Read more →BNTXPfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
Read more →BNTXPfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
Read more →BNTXPfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Read more →BNTXPfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19
Read more →BNTXStatement Regarding Cyber Attack on European Medicines Agency
Statement Regarding Cyber Attack on European Medicines Agency Today, we were informed by the European Medicines Agency (EMA) that the agency has been subject to a cyber attack and that some documents relating to the regulatory submission for Pfizer and BioNTech's COVID-19 vaccin
Read more →BNTXPfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
Read more →BNTXPfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA
Read more →BNTXBioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
Read more →BNTXPfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Read more →BNTXPfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Read more →BNTXBioNTech SE Quarterly Report for the Three and Nine Months ended
Quarterly Report for the Three and Nine Months ended September 30, 2020 Quarterly Report for the Three and Nine Months ended September 30, 2020 Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Financial Position 3 Interim Conden
Read more →BNTXPfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
Read more →BNTXBioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress • BNT162b2 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress Conference call and webcast scheduled for November 10, 2020 at 8:00 a.m. ET (2:00 p.m. CET) MAINZ, Germany, November 10, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"
Read more →BNTXBioNTech SE Pro Forma Financial Information BioNTech SE Pro Forma Financial Information Index Unaudited Pro Forma Condensed Combined Financial Information 3 Unaudited Pro Forma Condensed Combined Statement of Operations
Financial Information Pro Forma Financial Information Unaudited Pro Forma Condensed Combined Financial Information 3 Unaudited Pro Forma Condensed Combined Statement of Operations 5 Unaudited Pro Forma Condensed Combined Statement of Operations 6 Notes to Unaudited Pro
Read more →BNTXDuoBody -PD-L1 4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation Alexander Muik 1 , Isil Altintas 2 , Rachelle
MECHANISM OF ACTION OF FC-SILENCED PD-L1 4-1BB BSABS Fc-silenced PD-L1 4-1BB bsAbs are designed to re-activate anti-tumor immune responses by blockade of the PD-1:PD-L1 axis and conditional 4-1BB stimulation. PD-1:PD-L1 checkpoint blockade by the PD-L1-specific arm is constitut
Read more →BNTXPfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study • Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in p
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study NEW YORK and MAINZ, GERMANY, November 9, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate
Read more →BNTXBioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020
BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020
Read more →BNTXAn Open Letter from Pfizer Chairman and CEO Albert Bourla As we get closer to an important data readout from our COVID-19 vaccine program, I wanted to speak directly to the billions of people, millions of businesses and
An Open Letter from Pfizer Chairman and CEO Albert Bourla As we get closer to an important data readout from our COVID-19 vaccine program, I wanted to speak directly to the billions of people, millions of businesses and hundreds of governments around the world that are investing
Read more →BNTXBioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
Read more →BNTXBioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2 • Rolling review accepted by the EMA based on available preclinical and clinical data for BNT1
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2 NEW YORK and MAINZ, GERMANY, October 6, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to
Read more →BNTXBioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021 • Facility will become one of the largest mRNA manufacturing sites in Europe and the third site in the B
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021 MAINZ, Germany, September 17, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today announced the signing of a share purchase agreement wi
Read more →BNTXBioNTech to Receive up to 375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162 • The German Federal Ministry of Education and Research (BMBF) COVID-19 i
BioNTech to Receive up to 375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162 MAINZ, GERMANY, September 15, 2020 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today announced that it will receive a grant o
Read more →BNTXPfizer Contacts: Media Relations Amy Rose +1 (646) 592-3157 Amy.Rose@Pfizer.com Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com BioNTech Contacts: Media Relations Jasmina Alatovic +49 (0)613
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial NEW YORK and MAINZ, GERMANY, September 12 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to exp
Read more →BNTXPfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
Read more →BNTXPfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 • The proposed agreement is intended to provide a supply of 200 million doses and an optio
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 NEW YORK and MAINZ, GERMANY, September 9, 2020 - Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they had concluded exploratory talk
Read more →BNTXPfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19 • Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA
Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19 NEW YORK and MAINZ, GERMANY, September 9, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced preliminary preclinical data in mouse
Read more →BNTXBiopharma Leaders Unite to Stand with Science
Biopharma Leaders Unite to Stand with Science
Read more →BNTXPfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19 • In a Phase 1 study in the U.S., at 7 days after a second dose of 30ug, BNT162b2 elicited SARS-CoV-2-neutrali
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19 NEW YORK and MAINZ, GERMANY, August 20, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their
Read more →BNTXPfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature NEW YORK and MAINZ, GERMANY
Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature NEW YORK and MAINZ, GERMANY, August 12, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announc
Read more →BNTXof the Form 6-K of which this exhibit forms a part. Operating Results Overview BioNTech was founded in 2008 on the understanding that every cancer patient's tumor is unique and that in order to effectively address this c
BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress Conference call and webcast for analysts and investors scheduled for August 11, 2020 at 08:00 a.m. ET (2:00 p.m. CET) MAINZ, Germany, August 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX,
Read more →BNTXBioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
Read more →BNTXBioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020
BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020
Read more →BNTXPfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate • Supply to be provided over the course of 2021, subject to Health Canada approval • Agreement is part of Pfizer's and Bio
Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate KIRKLAND, Canada and MAINZ, Germany, August 5, 2020 - Pfizer Canada and BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today announced an agreement with the Government of Canada to suppl
Read more →BNTXBioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China • Phase 1 study will evaluate safety and immunogenicity in Chinese participants to support potential reg
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China MAINZ, Germany, and SHANGHAI, China, August 5, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") and Shanghai Fosun Pharmaceutical (Group)
Read more →BNTXBioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo (cemiplimab) Combination in Melanoma • BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BN
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo (cemiplimab) Combination in Melanoma MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today announced a strategic collaboration with R
Read more →BNTXPfizer and BioNTech to Supply Japan With 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate • Supply of 120 million doses to be provided in the first half of 2021, subject to regulatory approval Ȃ
Pfizer and BioNTech to Supply Japan With 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate NEW YORK and MAINZ, GERMANY, July 31, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfar
Read more →BNTXBioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature • Preliminary Phase 1 results from Lipo-MERIT trial with data from 89 patients highlight favorable tolerability profile of BNT111 in a
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) - BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced today the publication of interim Phase 1 data for the Company's FixVac cancer vaccin
Read more →BNTXPfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study • Companies advance nucleoside-modified messenger RNA (modRNA) candidate BNT162b2, which encodes
Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study NEW YORK, USA and MAINZ, GERMANY, July 27, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) P
Read more →BNTXBioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares
BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares Mainz, Germany, July 27, 2020 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company ) announced today the closing of its previously announced underwritten offering (the
Read more →BNTXBioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering
BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering MAINZ, Germany, July 22, 2020 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company ) announced today the pricing of its previously announced underwritten offering and terms o
Read more →BNTXPfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 • U. S. government placed an initial order of 100 million doses for $1
Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 NEW YORK and MAINZ, GERMANY, July 22, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an
Read more →BNTXBioNTech Announces Proposed Public Offerings
BioNTech Announces Proposed Public Offerings Mainz, Germany, July 21, 2020 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company ) announced today the proposed public offerings described below. The completion of the proposed public offerings is subject to market a
Read more →BNTXPfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 • Thirty million doses expected to be delivered in 2020 and 2021, subject to r
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 NEW YORK and MAINZ, GERMANY, July 20, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the United
Read more →BNTXPfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data • The data further demonstrated the ability of BNT162b1 to elicit high SARS-CoV
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data MAINZ, GERMANY and NEW YORK, USA, July 20, 2020 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") and Pfizer Inc. (NYSE: PFE) today anno
Read more →BNTXPfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2 Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 20
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020 NEW YORK, USA, and MAINZ, GERMANY, July 13, 2020 - Pfizer Inc. (NYSE: PFE)
Read more →BNTXBioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
BioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Read more →BNTXPfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2 • In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical tria
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2 NEW YORK, USA, and Mainz, GERMANY, July 1, 2020 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today announc
Read more →BNTXBioNTech to Raise USD 250 Million in Private Placement
BioNTech to Raise USD 250 Million in Private Placement MAINZ, Germany, June 29, 2020 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases,
Read more →BNTXBioNTech SE, Mainz, Germany Annual General Meeting in Munich, Germany, 26 June 2020 Voting results - Overview - Only the German version is binding Agenda Item 2 Approval of the actions of the Management Board - accepted
BioNTech SE, Mainz, Germany Annual General Meeting in Munich, Germany, 26 June 2020 Voting results - Overview - Only the German version is binding Agenda Item 2 Approval of the actions of the Management Board - accepted 152,033,174 Number of shares for which valid votes were
Read more →BNTXDr Braiteh has the following relationships to disclose: Honoraria from Abbott Nutrition, Amgen, ARIAD, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genentech/R
Braiteh F,1 LoRusso P,2 Balmanoukian A,3 Klempner S,3 Camidge DR,4 Hellmann MD,5 Gordon M,6 Bendell J,7 Mueller L,8 Sabado R,8 Twomey P,8 Delamarre L,8 Huang J,8 Yadav M,8 Zhang J,9 McDonald P,8 Muller F,10 Derhovanessian E,10 Tureci O,10 Sahin U,10 Siu LL11 1Comprehensive Cancer
Read more →BNTXDr Lopez has the following relationships to disclose: Research grant funding: Roche/Genentech, Basilea, Genmab Ad board: Basilea Disclosures Lopez j, et al. Phase Ib of of R07198457 https//bit.Iy/3gjdHA2 Clinical Benefit
Lopez J,1 Camidge DR,2 Iafolla M,3 Rottey S,4 Schuler M,5 Hellmann MD,6 Balmanoukian A,7 Dirix L,8 Gordon M,9 Sullivan RJ,10 Henick BS,11 Drake C,11 Wong KM,12 LoRusso P,13 Ott PA,14 Fong L,15 Schiza A,16 Yachnin J,17 Ottensmeier C,18 Braiteh F,19 Bendell J,20 Leidner R,21 Fisher
Read more →BNTXThe investments we have made to develop our vaccine platform over the past 12 years have been instrumental in enabling us to develop our C OVID -19 vaccine program me rapidly in response t o the global health crisis," sa
Investment Plan for Europe: European Investment Bank to provide BioNTech with up to 100 million in debt financing for COVID-19 vaccine development and manufacturing The European Investment Bank (EIB) and BioNTech SE (Nasdaq: BNTX, BioNTech) today concluded a 100 million debt fin
Read more →BNTXInvestment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing
Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing
Read more →BNTXBioNTech Announces First Quarter 2020 Financial Results and Corporate Progress
BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress
Read more →BNTXBioNTech completes acquisition of Neon Therapeutics Mainz, Germany and Cambridge, USA
BioNTech completes acquisition of Neon Therapeutics Mainz, Germany and Cambridge, USA May 6, 2020 BioNTech (Nasdaq: BNTX, BioNTech or the Company ) announced today the closing of the Neon Therapeutics, Inc. (Nasdaq: NTGN, Neon ) acquisition through an all-stock transaction. The
Read more →BNTXPfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program • First participants dosed at NYU Grossman School of Medicine and University of Maryland School o
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program NEW YORK, USA, and MAINZ, Germany, May 5, 2020 (GLOBE NEWSWIRE) - Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants
Read more →BNTXBioNTech to Report First Quarter 2020 Financial Results and Operational Update on May 12, 2020
BioNTech to Report First Quarter 2020 Financial Results and Operational Update on May 12, 2020
Read more →BNTXBioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany MAINZ, Germany, and
BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany MAINZ, Germany, and NEW YORK, USA, April 29, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") and Pfizer Inc. (NYSE: PFE
Read more →BNTXBioNTech Media Relations Jasmina Alatovic Senior Manager Global External Communications Tel: +49 (0)6131 9084 7640 or +49 (0)151 1978 1385 E-mail: Media@biontech.de BioNTech Investor Relations Sylke Maas, Ph.D. VP Invest
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates MAINZ, Germany, and NEW YORK, USA, April 22, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company
Read more →BNTXBioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
Read more →BNTXJPT Launches Broad Spectrum of COVID-19 Peptide Tools for Immune Monitoring, Vaccine & Diagnostics Development Berlin, Germany
JPT Launches Broad Spectrum of COVID-19 Peptide Tools for Immune Monitoring, Vaccine & Diagnostics Development Berlin, Germany, April 22, 2020 (GLOBE NEWSWIRE) - JPT Peptide Technologies (JPT) announces the launch of ready-to-use peptide tools to study and profile the immune res
Read more →BNTXPfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development • Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe,
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development MAINZ, Germany, and NEW YORK, USA, April 9, 2020 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), and Pfizer Inc. (NYSE: PFE) today disclosed additional det
Read more →BNTXBioNTech Announces Full Year 2019 Financial Results and Corporate Update • BNT111 FixVac Melanoma registrational trial start planned for 2H 2020 • BNT121 (iNeST) adjuvant Phase 2 study in NSCLC to start in
BioNTech Announces Full Year 2019 Financial Results and Corporate Update MAINZ, Germany, March 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatme
Read more →BNTXBioNTech to report full year financial results for 2019 and provide corporate update on the fourth quarter on March 31, 2020
BioNTech to report full year financial results for 2019 and provide corporate update on the fourth quarter on March 31, 2020
Read more →BNTXPfizer and BioNTech to Co-develop Potential COVID-19 Vaccine • Companies will jointly develop BioNTech's mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection • Collaboration aims to accelerate
Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine NEW YORK, USA and MAINZ, Germany, March 17, 2020 - Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech) today announced that the companies have agreed to a letter of intent regarding the co-devel
Read more →BNTXBioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat
BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat
Read more →BNTXBioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China • BioNTech and Fosun Pharma will jointly conduct clinical trials of BNT162 in China, leveraging BioNTech's proprietary mRNA vaccine techn
BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China Mainz, Germany and Shanghai, China, March 16, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma" or "Group"; Stock Symbol:
Read more →BNTXpartnerships to develop mRNA vaccines for infectious diseases, including with Pfizer, The University of Pennsylvania, The Bi ll and Melinda Gates Foundation and Fosun Pharma. About BioNTech Biopharmaceutical New Technolo
BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat Mainz, Germany, March 16, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") provides further details today on the Company's R&D effort, "Project Light
Read more →BNTXBioNTech Announces Commencement of Public Offering of American Depositary Shares Mainz, Germany
BioNTech Announces Commencement of Public Offering of American Depositary Shares Germany, February 3, 2020 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company ) announced today, that it has filed a registration statement on Form F-1 with the United States Securi
Read more →BNTXBioNTech to acquire Neon to strengthen global leadership position in T cell therapies Further expands BioNTech s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies Mainz, Germany and Cambridge, Massachusetts January 16, 2020 BioNTech (Nasdaq: BNTX, BioNTech ) and Neon Therapeutics, Inc. (Nasdaq: NTGN, Neon ) today announced that they have entered into a
Read more →BNTXBioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion Mainz, Germany
BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion Mainz, Germany, January 13, 2020 (GLOBE NEWSWIRE) - BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced today that the Supervisory Board has appointed Ryan Richa
Read more →BNTXBioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science
BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science
Read more →BNTXPRESS RELEASE
BioNTech Announces Publication of Preclinical Data for first-in-kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science Mainz, Germany, January 2, 2020 (GLOBE NEWSWIRE) - BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced today a publication in Science
Read more →BNTXBioNTech to Present at the 38th Annual J.P. Morgan Healthcare Conference
BioNTech to Present at the 38th Annual J.P. Morgan Healthcare Conference
Read more →BNTXJOINT PRESS RELEASE 17. December 2019 European Investment Bank provides funding of 50 million to BioNTech as part of the Investment Plan for Europe Funds will support BioNTech's research and development of cancer treatme
European Investment Bank provides funding of 50 million to BioNTech as part of the Investment Plan for Europe The European Investment Bank (EIB) and BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company") announced today the signing of a contract which provides financing of 50 m
Read more →BNTXEuropean Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe
European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe
Read more →BNTXBioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results • Successfully transferred IND for BNT321 to BioNTech . All necessary safety and other reports and an updated protocol fil
BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results Conference call and webcast (in English) scheduled for November 14, 2019 at 08:00 a.m. ET (2:00 p.m. CET) MAINZ, GERMANY, NOVEMBER 14, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX,
Read more →BNTXBioNTech to Report Third Quarter 2019 Financial Results and Operational Progress on November 14, 2019
BioNTech to Report Third Quarter 2019 Financial Results and Operational Progress on November 14, 2019
Read more →BNTXBioNTech Announces Pricing of Initial Public Offering
BioNTech Announces Pricing of Initial Public Offering
Read more →BNTXBioNTech Announces Commencement of Initial Public Offering
BioNTech Announces Commencement of Initial Public Offering
Read more →BNTXBioNTech and SMP to evaluate SMP's next generation technology for BioNTech products
BioNTech and SMP to evaluate SMP's next generation technology for BioNTech products
Read more →BNTXBioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer
BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer
Read more →BNTXBioNTech Secures USD 270 Million in Series A Financing
BioNTech Secures USD 270 Million in Series A Financing
Read more →BNTXBioNTech AG Enters into Licensing Agreement with CELLSCRIPT, LLC as it Advances Development of Messenger RNA Encoding Bispecific Antibodies and other Therapeutic Proteins
BioNTech AG Enters into Licensing Agreement with CELLSCRIPT, LLC as it Advances Development of Messenger RNA Encoding Bispecific Antibodies and other Therapeutic Proteins
Read more →BNTXNature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME
Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME
Read more →BNTXNature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies
Nature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies
Read more →BNTXBioNTech to Present Interim Phase I/II Data for Investigational mRNA Vaccine in Melanoma Patients at AACR Annual Meeting 2017
BioNTech to Present Interim Phase I/II Data for Investigational mRNA Vaccine in Melanoma Patients at AACR Annual Meeting 2017
Read more →BNTXBioNTech to Present at Cowen and Company’s 37th Annual Health Care Conference
BioNTech to Present at Cowen and Company’s 37th Annual Health Care Conference
Read more →BNTXBioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017
BioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017
Read more →BNTXBioNTech to Enter Into Worldwide Strategic Collaboration With Genentech to Develop Individualized mRNA Cancer Therapies
BioNTech to Enter Into Worldwide Strategic Collaboration With Genentech to Develop Individualized mRNA Cancer Therapies
Read more →BNTXNature Publication Describes First Example of a Clinically Applicable and Systemic mRNA Cancer Immunotherapy Vaccine
Nature Publication Describes First Example of a Clinically Applicable and Systemic mRNA Cancer Immunotherapy Vaccine
Read more →BNTXBayer and BioNTech Join Forces to Develop Innovative New mRNA Vaccines and Therapeutics for Animal Health Applications
Bayer and BioNTech Join Forces to Develop Innovative New mRNA Vaccines and Therapeutics for Animal Health Applications
Read more →BNTXSiemens and BioNTech Cooperate on Production of Personalized Cancer Vaccines
Siemens and BioNTech Cooperate on Production of Personalized Cancer Vaccines
Read more →BNTXBioNTech Launches MammaTyper® Breast Cancer Diagnostic Test in Europe
BioNTech Launches MammaTyper® Breast Cancer Diagnostic Test in Europe
Read more →BNTXBioNTech Signs Co-Development and Commercialization Agreement in Immuno-Oncology
BioNTech Signs Co-Development and Commercialization Agreement in Immuno-Oncology
Read more →BNTXBreakthrough Development in Cancer Immunology Published in Nature
Breakthrough Development in Cancer Immunology Published in Nature
Read more →BNTXEU-funded Consortium Led by Immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer
EU-funded Consortium Led by Immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer
Read more →BNTXBioNTech AG and Ganymed Pharmaceuticals AG Open New Research Headquarters in Mainz, Germany
BioNTech AG and Ganymed Pharmaceuticals AG Open New Research Headquarters in Mainz, Germany
Read more →BNTXSierk Pötting to be the New CFO (Chief Financial Officer) of BioNTech Group
Sierk Pötting to be the New CFO (Chief Financial Officer) of BioNTech Group
Read more →BNTXNew EU-Funded Consortium to Develop Fully Personalized Cancer Vaccines for Brain Cancer Patients
New EU-Funded Consortium to Develop Fully Personalized Cancer Vaccines for Brain Cancer Patients
Read more →BNTXBioNTech AG Appoints Sean Marett as COO (Chief Operating Officer)
BioNTech AG Appoints Sean Marett as COO (Chief Operating Officer)
Read more →Competitive Position
How BNTX ranks across every disease it competes inCompetitive Position is a premium feature
See how BNTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial